MENU
+Compare
KNSA
Stock ticker: NASDAQ
AS OF
Sep 24 closing price
Price
$36.09
Change
-$0.24 (-0.66%)
Capitalization
2.67B

KNSA stock forecast, quote, news & analysis

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases... Show more

KNSA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. KNSA showed earnings on July 29, 2025. You can read more about the earnings report here.
Interact to see
Advertisement
A.I.Advisor
a Summary for KNSA with price predictions
Sep 23, 2025

KNSA's RSI Oscillator leaves overbought zone

The 10-day RSI Oscillator for KNSA moved out of overbought territory on September 15, 2025. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 39 instances where the indicator moved out of the overbought zone. In of the 39 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 19, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on KNSA as a result. In of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for KNSA turned negative on September 16, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where KNSA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

KNSA broke above its upper Bollinger Band on September 08, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 70 cases where KNSA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where KNSA advanced for three days, in of 306 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 147 cases where KNSA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. KNSA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock slightly better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.402) is normal, around the industry mean (17.127). KNSA's P/E Ratio (721.800) is considerably higher than the industry average of (73.989). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.952). KNSA has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.030). P/S Ratio (5.079) is also within normal values, averaging (45.814).

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are ZOETIS (NYSE:ZTS), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), BioCryst Pharmaceuticals (NASDAQ:BCRX), Avadel Pharmaceuticals plc (NASDAQ:AVDL), Tilray Brands (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 3.87B. The market cap for tickers in the group ranges from 5.57K to 63.66B. AGN holds the highest valuation in this group at 63.66B. The lowest valued company is BGPPF at 5.57K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was 6%. For the same Industry, the average monthly price growth was 26%, and the average quarterly price growth was 69%. RGTLF experienced the highest price growth at 991%, while ZYBT experienced the biggest fall at -48%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was 25%. For the same stocks of the Industry, the average monthly volume growth was -54% and the average quarterly volume growth was 78%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 64
Price Growth Rating: 54
SMR Rating: 83
Profit Risk Rating: 90
Seasonality Score: -21 (-100 ... +100)
View a ticker or compare two or three
KNSA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a manufacturer of pharmaceutical products

Industry PharmaceuticalsGeneric

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
2 Church Street
Phone
+44 8081896257
Employees
297
Web
https://www.kiniksa.com